Marc Casper Sells 5,000 Shares of Thermo Fisher Scientific (NYSE:TMO) Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc Casper sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Thermo Fisher Scientific Trading Down 3.3%

TMO opened at $501.72 on Friday. The firm has a 50 day simple moving average of $567.28 and a 200 day simple moving average of $548.32. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The company has a market cap of $186.38 billion, a price-to-earnings ratio of 28.28, a price-to-earnings-growth ratio of 2.99 and a beta of 0.96. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. The firm had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the firm earned $6.10 earnings per share. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be issued a $0.47 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.70%.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several institutional investors have recently added to or reduced their stakes in the stock. Union Savings Bank bought a new position in Thermo Fisher Scientific during the 4th quarter worth about $856,000. Bayban bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $93,000. Pure Financial Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 6.2% during the fourth quarter. Pure Financial Advisors LLC now owns 1,407 shares of the medical research company’s stock worth $815,000 after buying an additional 82 shares during the period. Rehmann Capital Advisory Group raised its position in Thermo Fisher Scientific by 1.6% in the 4th quarter. Rehmann Capital Advisory Group now owns 2,136 shares of the medical research company’s stock valued at $1,238,000 after buying an additional 34 shares during the last quarter. Finally, SHP Wealth Management bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $102,000. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price on the stock in a report on Sunday, December 7th. HSBC raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. The Goldman Sachs Group initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, December 9th. They issued a “buy” rating and a $685.00 target price for the company. Evercore reissued an “outperform” rating and set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Finally, UBS Group reissued a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $633.68.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.